Cost analysis of Voriconazole versus Caspofungin for Primary Therapy of invasive Aspergillosis among High-Risk Hematologic Cancer Patients in China

Published real-world studies suggested voriconazole (Vfend) may provide reduced length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs compared to caspofungin (Cancidas) in invasive aspergillosis (IA) patients. We performed a cost analysis of voriconazole versus caspofungin as first-line antifungal treatment for IA among patients with prolonged neutropenia or undergoing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from a Chinese hospital perspective.

Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: X. Gao, M. Xue, J. Stephens, Y. Chen, S. Haider, C. Charbonneau Source Type: research